ALKYNYL-SUBSTITUTED HETEROCYCLIC COMPOUND, METHOD FOR PRODUCTION THEREOF AND USE THEREOF IN MEDICINE Russian patent published in 2020 - IPC C07D231/14 C07D231/44 C07D401/04 C07D401/06 C07D401/14 C07D403/04 C07D403/06 C07D403/14 A61K31/4155 A61K31/454 A61P35/00 

FIELD: chemistry.

SUBSTANCE: invention relates to organic chemistry and specifically to a compound of formula (II), or an isomer thereof, or a pharmaceutically acceptable salt thereof:

.

In formula II: R¹ denotes H or -NHR³; R³ represents H, C₁-₆ alkyl or 4–6 membered heterocyclyl, wherein alkyl and heterocyclyl is optionally substituted with halo, -OR⁵, C₁-₆ alkyl, C_3-6 cycloalkyl, or 4–6 membered heterocyclyl; X is absent or represents C₁-₆ alkylene; Y is absent or is C_3-6 cycloalkylene or 4–6-member heterocyclylene; Z is cyano,

bond a is a double bond or triple bond; in the event that said bond is a double bond, each R^a, R^b and R^c are independently H, halogen or C₁-₆ alkyl, wherein alkyl is optionally substituted with -OC_1-2 alkyl or -N(C_1-2 alkyl)₂; in the event that said bond is a triple bond, R^a and R^c are absent and R^b is H or C₁-₆ alkyl; G^a, G^b, G^c and G^d, each independently selected from a group consisting of H, halogen, -OR⁵ and -C(O)NR⁶R⁷; R⁴, R⁵, R⁶ and R⁷, each independently represent H or C₁-₆ alkyl, wherein n in formula II is optionally substituted by ²N. Also presented is a pharmaceutical composition and a method of treating.

EFFECT: technical result: novel organic compounds acting as fibroblast growth factor receptor (FGFR) inhibitor.

11 cl, 2 tbl, 34 ex